Journal of Endocrinological Investigation

, Volume 39, Issue 12, pp 1465–1474 | Cite as

Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association

  • B. Biondi
  • L. Bartalena
  • L. Chiovato
  • A. Lenzi
  • S. Mariotti
  • F. Pacini
  • A. Pontecorvi
  • P. Vitti
  • F. Trimarchi
Consensus Statement

Abstract

Levothyroxine (L-T4) is recommended as lifelong replacement therapy for hypothyroidism. Recent clinical and experimental data support the addition of levotriiodothyronine (L-T3) treatment in some selected hypothyroid patients when their symptoms persist and their quality of life remains impaired despite adequate L-T4 monotherapy. An increase in L-T3 prescriptions has been recently observed in Italy due to availability of different L-T3 formulations, making it possible to clinicians to prescribe L-T3 alone or in combination with L-T4. The aim of the present position statement was to define the correct clinical indications, schedule, duration of treatment and contraindications of combined treatment with L-T4 and L-T3 in hypothyroid patients in an attempt to guide clinicians and to avoid potential adverse effects of overtreatment.

Keywords

Hypothyroidism Replacement therapy TSH-suppressive therapy l-Thyroxine l-Triiodothyronine Deiodinases Clinical symptoms Quality of life Cognition Mood Depression Body weight Heart rate and patient preference for combined therapy Thyroidectomized patients Polymorphism in type 2 deiodinase gene 

References

  1. 1.
    Roberts CG, Ladenson PW (2004) Hypothyroidism. Lancet 363:793–803CrossRefPubMedGoogle Scholar
  2. 2.
    Biondi B, Wartofsky L (2014) Treatment with thyroid hormone. Endocr Rev 35:433–512CrossRefPubMedGoogle Scholar
  3. 3.
    Canaris GJ, Manowitz NR, Mayor G, Ridgway EC (2000) The Colorado thyroid disease prevalence study. Arch Intern Med 160:526–534CrossRefPubMedGoogle Scholar
  4. 4.
    Biondi B, Klein I (2004) Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 24:1–13CrossRefPubMedGoogle Scholar
  5. 5.
    Biondi B, Cooper DS (2008) The clinical significance of subclinical thyroid dysfunction. Endocr Rev 29:76–131CrossRefPubMedGoogle Scholar
  6. 6.
    Rodondi N, den Elzen WP, Bauer DC et al (2010) Thyroid studies collaboration. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304:1365–1374CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gencer B, Collet TH, Virgini V et al (2012) Thyroid studies collaboration. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 126:1040–1049CrossRefPubMedGoogle Scholar
  8. 8.
    Garber JR, Cobin RH, Gharib H et al (2012) American Association of Clinical Endocrinologists and American Thyroid Association taskforce on hypothyroidism in adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22:1200–1235CrossRefPubMedGoogle Scholar
  9. 9.
    Jonklaas J, Bianco AC, Bauer AJ et al (2014) American Thyroid Association task force on thyroid hormone replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid 24:1670–1751CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP (2012) ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 1:55–71CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Biondi B, Wartofsky L (2012) Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? J Clin Endocrinol Metab 97:2256–2271CrossRefPubMedGoogle Scholar
  12. 12.
    Mitchell AL, Hickey B, Hickey JL, Pearce SH (2009) Trends in thyroid hormone prescribing and consumption in the UK. BMC Public Health 9:132–211CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hannemann A, Friedrich N, Haring R et al (2010) Thyroid function tests in patients taking thyroid medication in Germany: results from the population-based Study of Health in Pomerania (SHIP). BMC Res Notes 3:227–231CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Biondi B, Celi F, Duntas L et al (2015) Terapia sostitutiva combinata con L-T4 e L-T3 nell’ipotiroidismo. L’Endocrinologo 16:264–268Google Scholar
  15. 15.
    Biondi B, Bartalena L, Cooper DS et al (2015) The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J 4(3):149–163CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR (2002) Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38–89CrossRefPubMedGoogle Scholar
  17. 17.
    Gereben B, McAninch EA, Ribeiro MO, Bianco AC (2015) Scope and limitations of iodothyronine deiodinases in hypothyroidism. Nat Rev Endocrinol 11:642–652CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Vita R, Saraceno G, Trimarchi F, Benvenga S (2014) Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J Clin Endocrinol Metab 99(12):4481–4486CrossRefPubMedGoogle Scholar
  19. 19.
    Hennessey JV, Malabanan AO, Haugen BR, Levy EG (2010) Adverse event reporting in patients treated with levothyroxine: results of the Pharmacovigilance Task Force survey of the American Thyroid Association, American Association of Clinical Endocrinologists, and The Endocrine Society. Endocr Pract 16:357–370CrossRefPubMedGoogle Scholar
  20. 20.
    Wartofsky L (2002) Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. Expert Opin Pharmacother 3:727–732CrossRefPubMedGoogle Scholar
  21. 21.
    Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MK (2013) Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab 98:1982–1990CrossRefPubMedGoogle Scholar
  22. 22.
    Yavuz S, Linderman JD, Smith S, Zhao X, Pucino F, Celi FS (2013) The dynamic pituitary response to escalating-dose TRH stimulation test in hypothyroid patients treated with liothyronine or levothyroxine replacement therapy. J Clin Endocrinol Metab 98:E862–E866CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Celi FS, Zemskova M, Linderman JD et al (2011) Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab 96:3466–3474CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Jonklaas J, Burman KD. 2016 Daily Administration of Short-Acting Liothyronine Is Associated with Significant Triiodothyronine Excursions and Fails to Alter Thyroid-Responsive Parameters. Thyroid Google Scholar
  25. 25.
    Smith RN, Taylor SA, Massey JC (1970) Controlled clinical trial of combined triiodothyronine and thyroxine in the treatment of hypothyroidism. Br Med J 4:145–148CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Peters A, Ehlers M, Blank B et al (2000) Excess triiodothyronine as a risk factor of coronary events. Arch Intern Med 160:1993–1999CrossRefPubMedGoogle Scholar
  27. 27.
    Leese GP, Soto-Pedre E, Donnelly LA (2016) Liothyronine use in a 17 year observational population-based study—the tears study. Clin Endocrinol. doi:10.1111/cen.13052
  28. 28.
    Escobar-Morreale HF, Obregon MJ, Escobar del Rey F, Morreale de Escobar G (1995) Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest 96:2828–2838CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Escobar-Morreale HF, Rey F, Obregon MJ, Escobar GM (1996) Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology 137:2490–2502PubMedGoogle Scholar
  30. 30.
    Werneck de Castro JP, Fonseca TL, Ueta CB et al (2015) Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. J Clin Invest 125:769–781CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Saravanan P, Chau WF, Roberts N et al (2002) Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol 57:577–585CrossRefGoogle Scholar
  32. 32.
    Panicker V, Evans J, Bjøro T et al (2009) A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clin Endocrinol 71:574–580CrossRefGoogle Scholar
  33. 33.
    Wekking EM, Appelhof BC, Fliers E et al (2005) Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 153:747–753CrossRefPubMedGoogle Scholar
  34. 34.
    Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L (2006) Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 91:2592–2599CrossRefPubMedGoogle Scholar
  35. 35.
    Ma C, Xie J, Huang X, Wang G et al (2009) Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. Nucl Med Commun 30:586–593CrossRefPubMedGoogle Scholar
  36. 36.
    Joffe RT, Brimacombe M, Levitt AJ, Stagnaro-Green A (2007) Treatment of clinical hypothyroidism with thyroxine and triiodothyronine: a literature review and metaanalysis. Psychosomatics 48:379–384CrossRefPubMedGoogle Scholar
  37. 37.
    Nygaard B, Jensen EW, Kvetny J, Jarløv A, Faber J (2009) Effect of combination therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol 161:895–902CrossRefPubMedGoogle Scholar
  38. 38.
    Schmidt U, Nygaard B, Jensen EW et al (2013) Peripheral markers of thyroid function: the effect of T4 monotherapy vs T4/T3 combination therapy in hypothyroid subjects in a randomized crossover study. Endocr Connect 2:55–60CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Fadeyev VV, Morgunova TB, Melnichenko GA, Dedov I (2010) Combined therapy with l-thyroxine and l-triiodothyronine compared to l-thyroxine alone in the treatment of primary hypothyroidism. Hormones 9:245–252CrossRefPubMedGoogle Scholar
  40. 40.
    WalshJ P, Shiels L, Lim EM et al (2003) Combined thyroxine/liothyronine treatment does not improve well-being, quality of life or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab 88:4543–4550CrossRefGoogle Scholar
  41. 41.
    Bunevicius R, Kazanavicius G, Zalinkevicius R, Jr Prange A J (1999) Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 340:424–429CrossRefPubMedGoogle Scholar
  42. 42.
    Escobar-Morreale HF, Botella-Carretero JI et al (2005) Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 142:412–424CrossRefPubMedGoogle Scholar
  43. 43.
    Bunevicius R, Jakubonien N, Jurkevicius R et al (2002) Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves’ disease. Endocrine 18:129–133CrossRefPubMedGoogle Scholar
  44. 44.
    Wiersinga WM (2014) Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. Nat Rev Endocrinol 10:164–174CrossRefPubMedGoogle Scholar
  45. 45.
    Appelhof BC, Fliers E, Wekking EM et al (2005) Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 90:2666–2674CrossRefPubMedGoogle Scholar
  46. 46.
    Jonklaas J, Davidson B, Bhagat S, Soldin SJ (2008) Triiodothyronine levels in athyreotic individuals during Levothyroxine therapy. JAMA 299:769–777CrossRefPubMedGoogle Scholar
  47. 47.
    Gullo D, Latina A, Frasca F et al (2011) Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS ONE 6:e2255CrossRefGoogle Scholar
  48. 48.
    Ito M, Miyauchi A, Morita S et al (2012) TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur J Endocrinol 167:373–378CrossRefPubMedGoogle Scholar
  49. 49.
    Ito M, Miyauchi A, Kang S et al (2015) Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients. Eur J Endocrinol 173:333–340CrossRefPubMedGoogle Scholar
  50. 50.
    Carr D, McLeod DT, Parry G, Thornes HM (1988) Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol 28:325–333CrossRefGoogle Scholar
  51. 51.
    Al-Adsani H, Hoffer LJ, Silva JE (1997) Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab 82:1118–1125PubMedGoogle Scholar
  52. 52.
    Walsh JP, Ward LC, Burke V et al (2006) Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab 91:2624–2630CrossRefPubMedGoogle Scholar
  53. 53.
    Carr D, McLeod DT, Parry G, Thornes HM (1988) Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol 28:325–333CrossRefGoogle Scholar
  54. 54.
    Biondi B, Cooper DS (2010) Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 20:135–146CrossRefPubMedGoogle Scholar
  55. 55.
    Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133CrossRefPubMedGoogle Scholar
  56. 56.
    Panicker V, Saravanan P, Vaidya B et al (2009) Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 94:1623–1629CrossRefPubMedGoogle Scholar
  57. 57.
    Mentuccia D, Proietti-Pannunzi L, Tanner K et al (2002) Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the β3adrenergic receptor. Diabetes 51:880–883CrossRefPubMedGoogle Scholar
  58. 58.
    Estivalet A, Leiria LB, Dora JM et al (2010) D2 Thr92Ala and PPARγ2 Pro12Ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients. Obesity 19:825–832CrossRefPubMedGoogle Scholar
  59. 59.
    Dora JM, Machado WE, Rheinheimer J, Crispim D, Maia AL (2010) Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. Eur J Endocrinol 163:427–434CrossRefPubMedGoogle Scholar
  60. 60.
    Guo TW, Zhang FC, Yang MS et al (2004) Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of China. J Med Genet 41:585–590CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    He B, Li J, Wang G, Ju W et al (2009) Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog Neuropsychopharmacol Biol Psychiatry 33:986–990CrossRefPubMedGoogle Scholar
  62. 62.
    Taylor P, Okosieme O, Sayers A et al (2014) Effect of low thyroid hormone bioavailability on childhood cognitive development: data from the Avon Longitudinal Study of Parents and Children birth cohort. Lancet 383:S100CrossRefGoogle Scholar
  63. 63.
    de Jong FJ, Peeters RP, den Heijer T et al (2007) The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 92:636–640CrossRefPubMedGoogle Scholar
  64. 64.
    van der Deure WM, Appelhof BC, Peeters RP et al (2008) Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clin Endocrinol 69:804–811CrossRefGoogle Scholar
  65. 65.
    Roef GL, Rietzschel ER, De Meyer T et al (2013) Associations between single nucleotide polymorphisms in thyroid hormone transporter genes (MCT8, MCT10 and OATP1C1) and circulating thyroid hormones. Clin Chim Acta 425:227–232CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2016

Authors and Affiliations

  • B. Biondi
    • 1
  • L. Bartalena
    • 2
  • L. Chiovato
    • 3
  • A. Lenzi
    • 4
  • S. Mariotti
    • 5
  • F. Pacini
    • 6
  • A. Pontecorvi
    • 7
  • P. Vitti
    • 8
  • F. Trimarchi
    • 9
  1. 1.Department of Clinical Medicine and SurgeryUniversity of Naples Federico IINaplesItaly
  2. 2.Department of Clinical and Experimental Medicine, ASST dei Sette Laghi, Ospedale di CircoloUniversity of InsubriaVareseItaly
  3. 3.Unit of Internal Medicine and EndocrinologyFondazione Salvatore Maugeri and University of PaviaPaviaItaly
  4. 4.Department of Experimental Medicine, Medical Pathophysiology, Food and Science and Endocrinology SectionSapienza University of RomeRomeItaly
  5. 5.Endocrinology Unit, Department of Medical Sciences “M. Aresu”University of CagliariCagliariItaly
  6. 6.Department of Medical, Surgical and Neurological SciencesUniversity of SienaSienaItaly
  7. 7.Unità di EndocrinologiaUniversità Cattolica del Sacro CuoreRomeItaly
  8. 8.Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
  9. 9.Accademia Peloritana dei PericolantiUniversità di Messina MessinaItaly

Personalised recommendations